加拿大品牌药价格联合谈判机制及其对我国的启示

A Study on Joint Negotiation Mechanism of Canadian Brand Drug Prices and its Enlightenment to China

目前我国正在逐步建立药品价格谈判制度,但施行细则尚未正式颁布。加拿大2010年建立的泛加拿大药物联盟(p CPA,pan-Canadian Pharmaceutical Alliance),负责代表加拿大各省与制药厂商进行品牌药价格联合谈判,极大提高了品牌药价格谈判方法和流程的一致性,对我国药价谈判制度的设计和完善具有重要的指导意义。本文从范围、流程、依据、结果、组织结构设计等方面解构p CPA谈判流程,提出其对我国药价谈判实施目标、方法依据、流程效率、组织结构、意见反馈、法律救济、数据保密、参与机制等方面的启示。

A drug price negotiation system is building up in China, but the enforcement rules has not yet been formally promulgated. The p CPA（pan-Canadian Pharmaceutical Alliance） established in 2010 which is responsible for negotiating new brand drug prices with Pharmaceutical manufacturers on behalf of the Canadian provinces, has improved the consistency of pricing method and process, and has saved expenditure of public medical insurance. In this article, we overview the p CPA’s negotiation range,process, basis, result and governance to provide enlightenment in goal, method, basis,process, performance, governance, stakeholder feedback, legal remedy, data confidentiality, participating mechanism for price negotiation in China.